Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on KYOWA HAKKO KIRIN CO LTD
02/20 KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for stock compensa..
02/20 KYOWA HAKKO KIRIN : Notice regarding the revision of the remuneration system for..
02/17 KYOWA HAKKO KIRIN : Notice regarding the revision of the remuneration system for..
02/17 KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for stock compensa..
02/01 KYOWA HAKKO KIRIN : Establishes Kyowa Kirin Frontier Co., Ltd.
02/01 KYOWA HAKKO KIRIN : Announces Top-Line Results of Phase 3 Clinical Study of KHK7..
01/31 KYOWA HAKKO KIRIN : Notice of Recording of Extraordinary Losses in Non-consolida..
01/31 KYOWA HAKKO KIRIN : Establishes Kyowa Kirin Frontier Co., Ltd.(21KB)
01/31 KYOWA HAKKO KIRIN : Announces Top-Line Results of Phase 3 Clinical Study of KHK7..
01/06 Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation App..
01/05 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin International Announce Marketing ..
2016 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for final dividend
2016 KYOWA HAKKO KIRIN : New Cancer Therapy Findings from Kyowa Hakko Kirin Co. Ltd. ..
2016 KYOWA HAKKO KIRIN : Announces Top-Line Results of Global Phase 3 Trial of KW-600..
2016 KYOWA HAKKO KIRIN : Announces Top-Line Results of Global Phase 3 Trial of KW-600..
2016 KYOWA HAKKO KIRIN : Data from Kyowa Hakko Kirin Co. Ltd. Advance Knowledge in Di..
2016 KYOWA HAKKO KIRIN : New Hypercalcemia Study Findings Have Been Reported by Inves..
2016 KYOWA HAKKO KIRIN : Application seeking Approval for Additional formulation of A..
2016 KYOWA HAKKO KIRIN : Launch of LUMICEF for Psoriasis Treatment, in Japan
2016 KYOWA HAKKO KIRIN : Application seeking Approval for Additional formulation of A..
2016 KYOWA HAKKO KIRIN : Launch of LUMICEF® for Psoriasis Treatment, in Japan
2016 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Pediatric and Adult Pha..
2016 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Phase 2 Study of KRN23 ..
2016 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Pediatric and Adult Pha..
2016 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Phase 2 Study of KRN23 ..
2016 Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the ..
2016 KYOWA HAKKO KIRIN : Reports Summarize Colon Cancer Study Results from Kyowa Hakk..
2016 L-Tyrosine Market 2016 - Ajinomoto, Kyowa Hakko Kogyo, Douglas Laboratories, ..
2016 Kyowa Hakko Kirin Announced Kyowa Medex Acquired approval for Insurance Cover..
2016 KYOWA HAKKO KIRIN : Announced Kyowa Medex Acquired approval for Insurance Covera..
2016 KYOWA HAKKO KIRIN : Patent Issued for Pharmaceutical Composition Comprising Anti..
2016 KYOWA HAKKO KIRIN : Researchers at Kyowa Hakko Kirin Co. Ltd. Release New Data o..
2016 KYOWA HAKKO KIRIN : LUMICEF® approved in Japan(112KB)
2016 Ultragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric P..
2016 KYOWA HAKKO KIRIN : US Food and Drug Administration Granted Breakthrough Therapy..
2016 KYOWA HAKKO KIRIN : US Food and Drug Administration Granted Breakthrough Therapy..
2016 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for interim dividend
2016 KYOWA HAKKO KIRIN : Studies from Kyowa Hakko Kirin Co. Ltd. Describe New Finding..
2016 KYOWA HAKKO KIRIN : Researchers from Kyowa Hakko Kirin Co. Ltd. Provide Details ..
2016 Medgenics Enters into Agreement with Kyowa Hakko Kirin
2016 KYOWA HAKKO KIRIN : Announces Preliminary Results from Pivotal Phase 2 Study of ..
2016 GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson %..
2016 KYOWA HAKKO KIRIN : Announces Preliminary Results from Pivotal Phase 2 Study of ..
2016 KYOWA HAKKO KIRIN : Studies from Kyowa Hakko Kirin Co. Ltd. Add New Findings in ..
2016 KYOWA HAKKO KIRIN : Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal ..
2016 KYOWA HAKKO KIRIN : Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal ..
2016 Positive benralizumab results in severe asthma
2016 KYOWA HAKKO KIRIN : Borders-based pharma firm in Japanese-led rebrand
2016 KYOWA HAKKO KIRIN : ProStrakan rebrands as Kyowa Kirin International PLC
2016 KYOWA HAKKO KIRIN : Medicine firm aims to unify its image with a rebrand
2016 KYOWA HAKKO KIRIN : ProStrakan rebrands as Kyowa Kirin
2016 KYOWA HAKKO KIRIN : BioWa Announces Office Relocation to Princeton, NJ and appoi..
2016 KYOWA HAKKO KIRIN : Matters concerning controlling shareholders
2016 KYOWA HAKKO KIRIN : BioWa Announces Office Relocation to Princeton, NJ and appoi..
2016 KYOWA HAKKO KIRIN : Matters concerning controlling shareholders(44KB)
2016 KYOWA HAKKO KIRIN : Notice regarding allotment of stock acquisition rights (stoc..
2016 AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business ..
2016 ProStrakan acquires rights for drug easing side effect of pain pills
2016 KYOWA HAKKO KIRIN : Initiation of Operations for Drug Product Manufacturing Faci..
2016 AstraZeneca enters into agreement with ProStrakan for rights to Moventig in E..
2016 KYOWA HAKKO KIRIN : AstraZeneca sells drug for $70 million as divestment drive c..
2016 KYOWA HAKKO KIRIN : Entries Now Publicly Available from the 'Commitment to Life'..
2016 KYOWA HAKKO KIRIN : Change of Representative Directors at Kyowa Medex(31KB)
2016 KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for the purpose of..
2016 KYOWA HAKKO KIRIN : Announces FY2016-2020 Mid-term Business Plan(123KB)
2016 KYOWA HAKKO KIRIN : Consolidated Financial Summary Fiscal 2015(221KB)
2016 KYOWA HAKKO KIRIN : Appendix to the Consolidated Financial Summary Fiscal 2015(1..
2016 KYOWA HAKKO KIRIN : Results Presentation Fiscal 2015(1,924KB)
2016 KYOWA HAKKO KIRIN : Change in the Company Name of Western Pharmaceutical Subsidi..
2016 KYOWA HAKKO KIRIN : BioWa opens POTELLIGENT® Technology license to customers for..
2015 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for final dividend
2015 KYOWA HAKKO KIRIN : Launch of the Web Comic "The Story of Basic Immunology"
2015 KYOWA HAKKO KIRIN : Medex Launched "Liaison 25 -hydroxyvitamin D Total" in Japan
2015 KYOWA HAKKO KIRIN : Announces Commencement of Phase 3 Clinical Study of KHK7580 ..
2015 KYOWA HAKKO KIRIN : Consolidated Financial Summary Fiscal 2015 Third Quarter(110..
1  2  3Next
Advertisement
Financials ( JPY)
Sales 2017 351 800 M
EBIT 2017 -
Net income 2017 21 229 M
Finance 2017 30 227 M
Yield 2017 1,50%
P/E ratio 2017 41,08
P/E ratio 2018 34,71
EV / Sales 2017 2,64x
EV / Sales 2018 2,49x
Capitalization 958 116 M
More Financials
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Full-screen chart
Technical analysis trends KYOWA HAKKO KIRIN...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 2 040  JPY
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Koichiro Nishikawa Independent Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO L..2.72%8 445
ABBVIE INC-1.26%98 552
MERCK KGAA2.77%13 863
JAZZ PHARMACEUTICALS P..24.67%8 141
MALLINCKRODT PLC8.61%5 665
ZHANGZHOU PIENTZEHUANG..0.94%4 047
More Results